DIPA-1-9 Syrup for Upper Aerodigestive Tract Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications for upper aerodigestive tract discomfort, such as cough and throat irritation, have limited efficacy, rapid tolerance, adverse taste, and systemic side effects, failing to provide sustained relief without numbing or irritating the tissues.
Innovation Solution
The development of 1-Diisopropyl-phosphinoyl-nonane (DIPA-1-9), a di-alkyl-phosphinoyl-alkane, is topically applied in a small volume syrup to selectively activate TRPM8 receptors in the stratified epithelium of the pharynx and esophagus, providing a cooling sensation without pain or taste, with a prolonged duration of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications are used for upper aerodigestive tract discomfort, then cough suppression and irritation relief are achieved, but rapid tolerance develops and systemic side effects occur
Solution Approach 1:
The patent applies local quality by using a topical formulation that delivers the active ingredient specifically to the upper aerodigestive tract mucosa. The medication is applied locally to the throat and upper airway surfaces, creating high concentration at the target site while maintaining low systemic levels, thereby achieving sustained local efficacy without rapid tolerance development
Solution Approach 2:
The patent uses a topical delivery system as an intermediary between the active ingredient and the systemic circulation. This intermediary approach allows the medication to act directly on the upper aerodigestive tract tissues through topical application, bypassing first-pass metabolism and reducing systemic exposure that leads to tolerance and side effects
2Object-affected harmful factors
If local anesthetics are applied to relieve throat discomfort, then pain relief is achieved, but tissue numbing and impaired wound healing occur
Solution Approach 1:
The patent applies parameter changes by using a different mechanism of action (TRPM8 receptor activation producing cooling sensation) instead of sodium channel blockade. This changes the pharmacological parameter from anesthetics that block nerve conduction to compounds that produce a soothing cooling effect, thereby relieving pain without causing tissue numbing or impairing wound healing
Solution Approach 2:
The patent employs a topical formulation with short duration of action that can be reapplied as needed. The medication provides temporary relief through cooling sensation without accumulating in tissues or causing prolonged numbing effects, allowing repeated applications without the cumulative harmful effects of systemic anesthetics
3Productivity
If dextromethorphan and codeine are used for cough suppression, then cough frequency is reduced, but abuse potential and limited efficacy are increased
Solution Approach 1:
The patent extracts the cough-suppressing effect from the problematic opioid mechanism. By targeting TRPM8 receptors in the upper aerodigestive tract, the invention isolates the antitussive benefit while removing the abuse potential, sedation, and respiratory depression associated with codeine and dextromethorphan
Solution Approach 2:
The patent substitutes the opioid receptor mechanism with a TRPM8 channel activation mechanism. This replacement changes the pharmacological system from central nervous system opioid receptors to peripheral temperature-sensitive ion channels, achieving cough suppression through a different physiological pathway that does not produce abuse or sedation
4Quantity of substance
If first-generation antihistamines are used for cough associated with allergies, then nasal secretion drying is achieved, but sedation and dry mouth side effects occur
Solution Approach 1:
The patent applies local quality by using a topical formulation that acts locally on the upper aerodigestive tract mucosa without significant systemic absorption. This local action achieves the therapeutic effect of reducing secretions and relieving irritation without the systemic sedation and dry mouth effects associated with oral antihistamines
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DIPA-1-9 effectively suppresses sensory discomfort in the upper aerodigestive tract with rapid onset and long-lasting relief, inhibiting cough frequency and alleviating irritation without systemic cooling or adverse effects, making it suitable for treating conditions like cough, heartburn, and dyspnea.
Implementation Method 1
selectively activate TRPM8 receptors in the stratified epithelium of the pharynx and esophagus, providing a cooling sensation
Data Source
AI summary
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to a particular 1-di-alkyl-phosphinoyl-alkane, 1-(Diisopropyl-phosphinoyl)-nonane, referred to herein as “DIPA-1-9”. Surprisingly and unexpectedly, DIPA-1-9, is able to selectively treat (e.g., suppress) sensory discomfort arising from the lumenal epithelial lining of the pharynx and esophagus without side effects. Compared to structurally similar compounds, DIPA-1-9 did not have the problems of painful cold, stinging, or irritancy, or of adverse taste when applied in the oral cavity. To deliver the DIPA-1-9 to the lumenal epithelium of the pharynx and esophagus, an ideal formulation for delivery is a solution of DIPA-1-9 in syrup, at a concentration of 5 to 12 mg/mL and a delivery volume of less than 1 mL. The delivery unit can be a plastic vial with a design such that the syrup is poured onto the base of the tongue, next to the pillars of fauces. The DIPA-1-9 then reaches the nerve endings at the base of the epithelia and transduces signals of coolness and cold. Cooling of the pharyngeal and esophageal lining relieves discomfort and is useful for conditions such as throat irritation, pharyngitis, tonsillitis, cough, chronic cough, heartburn, chest pain, and esophagitis. Moreover, the elicitation of cooling in the pharynx and esophagus can be utilized to treat dysphagia, dyspepsia, and dyspnoea, and to enhance mucus expectoration in inflammatory airway disorders such as cystic fibrosis, asthma, and chronic obstructive pulmonary diseases (which includes bronchitis and bronchiectasis). A particularly preferred embodiment is DIPA-1-9 dissolved in a syrup vehicle in a delivery unit volume of less than 1 mL.